Merchant Alert: Q1 2026 Psychedelic Funding Update – Compass Pathways Secures Major Capital

Q1 2026 saw $348 million raised across 11 psychedelic financing events, a slight decline from Q4 2025. A substantial portion of this capital, approximately $350 million, was secured by Compass Pathways, a key developer in the psilocybin space. This significant funding empowers major industry players to advance R&D, potentially influencing the future availability and market dynamics of psychedelic-assisted therapies relevant to our merchant community.

The first quarter of 2026 recorded approximately $348 million in funding across 11 psychedelic financing events, a modest decrease from the prior quarter. Compass Pathways was the primary beneficiary, securing roughly $350 million. This capital injection comprised a $150 million public offering following a positive Phase 3 readout, alongside an additional $200 million from the exercise of outstanding warrants. Compass Pathways is currently progressing its Phase 3 psilocybin program for treatment-resistant depression (TRD), aiming for a new drug application submission to the FDA.

Sentinel Insight